Genetic science is a game-changer for medication safety and healthcare overall, and Coriell Life Sciences is leading the way in unlocking its full potential through precision medicine.
Coriell Life Sciences, a trusted and innovative precision medicine organization, is honored to accept two industry awards: EHIR's Fall 2020 Traction Award Healthcare Tech Outlook's Top Precision Medicine Providers in Europe
Coriell Life Sciences case study: A DNA analysis and precision medicine algorithm generates a detailed personalized medicine report for participants of the Teachers’ Retirement System of the State of Kentucky.
Coriell Life Sciences is rolling out a new tool in the fight against COVID-19: personalized COVID-19 Risk Scores designed to enable safer re-opening and return to work plans (especially given the recent release of the CDC guidelines for re-opening).
Coriell Life Sciences (CLS), a leading provider of molecular test interpretation and reporting, is offering its coronavirus analysis and reporting services to laboratories throughout the United States at no cost during this period of public health crisis.
Coriell Life Sciences, a trusted bioinformatics company, was proud to accept the Excellence Award in the Cost Containment category at the Pharmacy Benefit Management Institute’s (PBMI) 25th Annual National Conference in Orlando, FL.
The cost of genetic testing has steadily declined since the human genome was first mapped in 2003, allowing large employers, healthcare systems, and pension funds to adopt an upstream approach to preventative care by offering genetic testing and precision medicine as proactive wellness benefits.
Join Coriell Life Sciences at APHA 2019, the annual meeting and expo of the American Public Health Association, where the company will present its latest precision public health findings at the Genomics Forum on November 5 at 10:30 a.m. The APHA Annual Meeting, one of the nation’s most influential public health events, will be held November 2-6 in Philadelphia, PA.
Coriell Life Sciences has expanded its leadership team and announced three new roles. Chief Financial Officer William Testa, CPA, started on June 17; Chief Revenue Officer Jennifer Ferrang, MBA, joined the company on September 30; and Director of Precision Medicine Aissa Aifaoui, PharmD, Clinical Pathologist, began on October 15.
Collaborative research from Coriell Life Sciences and colleagues validates a growing body of evidence that supports the many benefits of molecular diagnosis of vaginitis over traditional microscopy. The study—one of the largest comprehensive explorations on diagnostic methods for infectious vaginitis—compared the accuracy of traditional microscopy results for Bacterial Vaginosis (BV) and Candida with newer molecular biology techniques.
KPMG’s Clinical Intelligence (KCI) platform is helping clinicians improve the quality of care by furnishing them with pharmacogenomics data – information about how genes interact with medicines – from Coriell Life Sciences (CLS), supported by Thermo Fisher Scientific’s leading genetic analysis platform and content.
New research from Coriell Life Sciences explores patient-specific changes in CYP2D6, a key gene involved in the metabolism of up to 25 percent of commonly prescribed drugs including many antipsychotics and antidepressants. There is growing concern for the nearly 40 million U.S. adults who take psychiatric medications that adverse drug events (ADEs) from therapeutic use of these medicines is amplifying the number of patients who visit emergency departments (EDs). Recent data demonstrate that 1 in 5 of these ED visits result in hospitalization.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right